drugset / Trial / NCT00337662

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

NCT00337662

Phase 4 Completed 628 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

Timeline

Start
2006-05
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 10 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Comparator Risperidone Other / unclassified 2 mg Oral
Comparator Risperidone Other / unclassified 6 mg Oral